KLRK1 and plasma cell myeloma: These results are consistent with findings from clinical trials of lenalidomide-refractory myeloma, where it was shown that pomalidomide in combination with dexamethasone increased CD56, CD16, NKG2D, and TIM-3 expression on NK cells and enhanced NK cell production of TNFα and IFNγ.18